CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Syneos Health and Science 37 Announce Strategic Partnership

Syneos Health and Science 37 Announce...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Avance Appoints New Business Development Manager APAC

Avance Appoints New Business...

The Growing Demand for Contract Research Organizations

The Growing Demand for Contract...

The Potential for Artificial Intelligence in Clinical Trials

The Potential for Artificial...

Craig Lipset Joins Member and Executive Advisor of MedVector

Craig Lipset Joins Member and...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Syneos Health and Science 37 Announce Strategic Partnership

Syneos Health and Science 37 Announce...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Avance Appoints New Business Development Manager APAC

Avance Appoints New Business...

The Growing Demand for Contract Research Organizations

The Growing Demand for Contract...

The Potential for Artificial Intelligence in Clinical Trials

The Potential for Artificial...

Craig Lipset Joins Member and Executive Advisor of MedVector

Craig Lipset Joins Member and...

Silo Pharma Partners with Zylo Therapeutics

Life Sciences Review Life Sciences Review | Thursday, May 20, 2021
Tweet

Sustained Transdermal delivery method to become essential for Alzheimers and Parkinsons patients with Dysphagia.


FREMONT, CA: Silo Pharma, a developmental stage biopharmaceutical firm focused on the use of psychedelics as a therapeutic, enters into a Joint Venture with Zylo Therapeutics.  This Joint Venture will utilize Zylos innovative sustained-release topical delivery system developed at Albert Einstein College of Medicine, leveraging Silo Pharma’s expertise in the use of psychedelics. The joint venture will explore the clinical development of ketamine using ZTIs Z-pod technology and offers for Silo Pharma to get an exclusive option for the clinical effect of psilocybin using ZTIs Z-pod technology as well.


Eric Weisblum, CEO of Silo Pharma, stated This Joint Venture is part of Silo Pharma’s vision of bringing therapeutics to patients in need.  The ability to offer Ketamine or Psilocybin in a time-released manner will enable us to explore both the safety and efficacy of the therapeutics while hopefully diminishing the hallucinogenic impacts of psychedelics.  We believe that Zylo’s patented technology will help to reach potential patients that suffer from Dysphagia, like both Alzheimers and Parkinsons patients.


Zylo Therapeutics is exceptionally excited to be entering into this partnership with Silo Pharma, a company with broad-ranging expertise in psychedelics. Ketamine is a versatile drug that continues to show promise with novel therapeutic indications. The company is looking forward to leveraging proprietary topical delivery technology to build a low-dose, sustained-release ketamine formulation that is safe and convenient for patients.


Silo Pharma. is a developmental stage biopharmaceutical organization focused on merging traditional therapeutics with psychedelic research for people suffering from depression, PTSD, Parkinsons, and other rare neurological diseases. Silos mission is to identify assets to license and fund the investigation, which the companies believe will be transformative to the well-being of patients and the health care sector.


Weekly Brief

loading
Top 10 CROs - 2021
> <
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue

Read Also

Role of Predictive Genomics in Sustainable Healthcare

Role of Predictive Genomics in Sustainable Healthcare

A Conversational AI Approach to Regulatory Intelligence

A Conversational AI Approach to Regulatory Intelligence

A rise in DNA Sequencing Market is expected in coming years

A rise in DNA Sequencing Market is expected in coming years

Omniabio Inc. Announces Private Investor

Omniabio Inc. Announces Private Investor
Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Lithuania's Vision to Become a Biotech Hub in Europe

Lithuania's Vision to Become a Biotech Hub in Europe

Bridging the Diversity Gap in Genomics

Bridging the Diversity Gap in Genomics

How does Biotechnology Provide Solutions to Human Needs?

How does Biotechnology Provide Solutions to Human Needs?
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/silo-pharma-partners-with-zylo-therapeutics--nwid-366.html